Clovis Oncology (NASDAQ:CLVS)’s share price was up 5.4% during trading on Tuesday . The company traded as high as $15.44 and last traded at $15.26. Approximately 1,290,547 shares traded hands during mid-day trading, a decline of 13% from the average daily volume of 1,485,821 shares. The stock had previously closed at $14.48.

A number of equities analysts have commented on CLVS shares. Cann reaffirmed a “hold” rating on shares of Clovis Oncology in a report on Friday, October 19th. Guggenheim assumed coverage on shares of Clovis Oncology in a report on Monday, September 17th. They set a “buy” rating for the company. BidaskClub raised shares of Clovis Oncology from a “strong sell” rating to a “sell” rating in a report on Thursday, October 18th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Clovis Oncology in a report on Tuesday, October 2nd. Finally, Leerink Swann assumed coverage on shares of Clovis Oncology in a report on Monday, September 24th. They set a “market perform” rating and a $30.00 price target for the company. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $56.32.

The firm has a market cap of $824.94 million, a PE ratio of -2.98 and a beta of 2.07. The company has a debt-to-equity ratio of 2.46, a quick ratio of 8.46 and a current ratio of 9.03.

Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings results on Tuesday, October 30th. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by ($0.11). Clovis Oncology had a negative net margin of 390.65% and a negative return on equity of 108.92%. The firm had revenue of $22.76 million for the quarter, compared to analyst estimates of $30.11 million. During the same period last year, the firm posted ($1.24) EPS. The business’s revenue was up 35.4% compared to the same quarter last year. On average, research analysts anticipate that Clovis Oncology will post -6.65 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. University of Notre Dame DU Lac raised its stake in shares of Clovis Oncology by 48.4% during the third quarter. University of Notre Dame DU Lac now owns 80,441 shares of the biopharmaceutical company’s stock valued at $2,363,000 after purchasing an additional 26,244 shares in the last quarter. Hsbc Holdings PLC bought a new stake in shares of Clovis Oncology during the third quarter valued at about $968,000. Alliancebernstein L.P. raised its stake in shares of Clovis Oncology by 48.4% during the third quarter. Alliancebernstein L.P. now owns 1,414,652 shares of the biopharmaceutical company’s stock valued at $41,548,000 after purchasing an additional 461,629 shares in the last quarter. Swiss National Bank raised its stake in shares of Clovis Oncology by 4.1% during the third quarter. Swiss National Bank now owns 87,050 shares of the biopharmaceutical company’s stock valued at $2,557,000 after purchasing an additional 3,400 shares in the last quarter. Finally, Zeke Capital Advisors LLC bought a new stake in shares of Clovis Oncology during the third quarter valued at about $268,000.

COPYRIGHT VIOLATION NOTICE: “Clovis Oncology (CLVS) Trading Up 5.4%” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2018/11/13/clovis-oncology-clvs-trading-up-5-4.html.

About Clovis Oncology (NASDAQ:CLVS)

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Featured Story: Fundamental Analysis and Individual Investors

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.